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Introduction
Generalized, chronic, ‘free-floating’ anxiety has been 
recognized as an important clinical condition for more 
than a century (Rickels & Rynn 2001). However, while 
there is strong agreement about the existence of gen-
eralized anxiety that is severe enough to warrant diag-
nosis and treatment, there is far less agreement about 
the features that define the condition and distinguish 
it from normal anxiety. This may be because anxiety 
is experienced occasionally by almost everyone, espe-
cially during times of stress. Furthermore, normal 
expressions of anxiety vary widely, with many people 
experiencing higher-than-average levels of anxiety 
without being considered to have a mental disorder.
Due in part to these challenges, the definition of 
generalized anxiety disorder (GAD) has changed more 
in the last three decades than perhaps any other mental 
disorder (Davidson et al. 2010). In its original instanti-
ation in DSM-III (APA 1980), GAD was defined as per-
sistent anxiety lasting at least one month and involving 
associated symptoms from three of four categories. As 
persistent anxiety is a feature of all anxiety disorders, 
GAD was treated as a ‘wastebasket’ or residual diag-
nostic category. It was assumed to be associated with 
relatively modest impairment. In DSM-III-R (APA 
1987), GAD changed from a residual diagnosis to an 
independent disorder defined centrally by pathological 
worry. To facilitate discrimination from normal worry, 
the worry in GAD was defined as generalized (related 
to multiple life circumstances), excessive, unrealistic, 
and accompanied by six of 18 associated symptoms of 
anxiety. Minimum duration was increased from one to 
six months to distinguish GAD from transient stress 
reactions. DSM-IV (APA 1994) established general-
ized, excessive, uncontrollable worry as the cardinal 
feature of GAD. To sharpen the separation from other 
anxiety disorders, associated symptoms were restricted 
to six symptoms of tension and vigilance that were 
most frequently observed in GAD patients, with three 
required for diagnosis. The disturbance was required 
to last at least six months and to cause clinically signifi-
cant distress or impairment.
The DSM-IV conceptualization of GAD was widely 
viewed as an improvement over earlier definitions 
(Ballenger et al. 2001). The emphasis on worry and a 
streamlined set of associated symptoms aided clinicians 
in detecting GAD and distinguishing it from closely 
related disorders (Marten et al. 1993; Chelminski & 
Zimmerman 2003), helping to raise diagnostic reli-
ability up to the level of other anxiety disorders (Brown 
et al. 2001). Despite these improvements, debates have 
persisted about the validity of GAD (Brown et al. 1994; 
Starcevic et al. 2012). A particularly controversial 
aspect of GAD has been its relationship with mood dis-
orders, especially major depressive disorder (MDD). 
Although associations are strong between all anxiety 
and mood disorders, GAD and MDD overlap the most 
in their comorbidity (Ruscio & Khazanov, 2017), clini-
cal features (Ehring & Watkins 2008; Watson 2009), and 
genetic risk (Kendler et al. 1992), leading some to ques-
tion the distinctness of these disorders (see Goldberg 
et al., 2010). DSM-IV dealt with the close relation-
ship between GAD and mood disorders by including 
a diagnostic hierarchy rule that prohibited a diagnosis 
of GAD when its symptoms occurred exclusively dur-
ing episodes of a mood disorder. The rationale was that 
depressed and manic individuals frequently present 
with heightened anxiety and agitation and that, when 
these symptoms wax and wane with other mood symp-
toms, they should be considered part of the mood dis-
order rather than an independent disorder (APA 1994). 
Although the hierarchy rule was intended to avoid 
extraneous diagnoses of GAD, subsequent clinical 
research suggested that cases subject to the hierarchy 
rule resembled patients with comorbid GAD-MDD 
much more closely than patients with MDD alone 
(Zimmerman & Chelminski 2003). Largely for this rea-
son (Andrews et al. 2010), the hierarchical exclusion 
with mood disorders was dropped from the definition 
of GAD in the recently published DSM-5 (APA 2013).
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Section II: The Disorders
This latest diagnostic revision has reopened ques-
tions about the validity of the GAD diagnosis and its 
separation from other mental disorders. It has also 
raised new questions about how GAD cases identi-
fied by DSM-IV differ from those identified by DSM-5. 
Comparing individuals diagnosed under the two 
 systems is important not only for establishing the 
validity of the new GAD criteria, but for determining 
the likely generalizability of prior research findings and 
treatment guidelines to DSM-5 GAD, ensuring conti-
nuity of research and clinical care (see Abel & Borkovec 
1995). To our knowledge, only two studies have com-
pared GAD diagnosed with and without the hierarchy 
rule, both using outpatient samples in specialty men-
tal health clinics in the United States (Zimmerman & 
Chelminski 2003; Lawrence et al. 2009). Those studies 
suggested that lifting the hierarchy rule yields a sizable 
number of new GAD cases and that the new cases are 
particularly severe, with a high burden of comorbidity 
and disability.
Although suggestive, these findings are limited in 
two important respects. First, help-seeking samples are 
known to differ systematically from the population at 
large in their severity and comorbidity (Berkson 1946). 
Representative community samples are not subject to 
these biases. In addition, because they include indi-
viduals who are not in treatment as well as those receiv-
ing treatment, community samples are well-suited to 
describing the proportion of those with a disorder who 
seek clinical care and the settings in which care is sought. 
Knowledge of these patterns aids clinicians in assessing 
and detecting GAD in a variety of service settings and 
aids policy-makers in estimating unmet need in the 
community. Second, data from countries other than the 
United States are needed. Most of what is known about 
GAD comes from a small number of economically 
developed countries (cf. Somers et al. 2006). Studying 
GAD in other parts of the globe is necessary, however, 
for separating universal features of the disorder from 
those that vary by country or culture (Lewis-Fernández 
et al. 2010). As the DSM system is intended to guide 
clinical diagnosis, treatment planning, and research and 
policy efforts around the world, cross-national informa-
tion about the GAD diagnosis is critical.
In this chapter, we used data from the WMH surveys 
to describe DSM-IV GAD and compare it to DSM-5 
GAD. By lifting the DSM-IV hierarchy rule barring 
the diagnosis of GAD during a mood disorder, we were 
able to compare cases identified by the two diagnostic 
systems within the same sample. We considered the 
implications of the diagnostic revision for the prevalence 
of GAD, its comorbidity with other mental disorders, its 
associations with role impairment and treatment seek-
ing, and its clinical course and socio-demographic cor-
relates. We examined the generalizability of results by 
performing analyses not only in the large cross-national 
sample, but within subgroups of countries that differ in 
economic development.
Methods
Data from all 29 WMH surveys are included in this 
report. The combined sample included 147,261 respond-
ents from 26 countries. As GAD was assessed in Part I, 
all analyses used the Part I sample except the comor-
bidity analyses, which were performed using the Part 
II sample to allow disorders assessed in Part II to be 
included.
The Composite International Diagnostic Interview 
(CIDI) 3.0 generates diagnoses of mental disorders 
using DSM-IV criteria. In the United States survey, life-
time GAD diagnoses based on the CIDI were shown to 
have good concordance with clinician-assigned diag-
noses based on the Structured Clinical Interview for 
DSM-IV (SCID; First et al. 2002), with an area under 
the Receiver Operating Characteristic (ROC) curve 
(AUC) of 0.83 (Ruscio et al. 2005). Similar analyses 
in a subset of four WMH surveys did not evaluate GAD 
in isolation, but found good concordance between 
CIDI and SCID diagnoses of any 12-month anxiety dis-
order including GAD (AUC = 0.88; Haro et al. 2006).
CIDI diagnoses of DSM-IV GAD are assigned 
when excessive, uncontrollable worry is reported 
about a number of events or activities, accompanied by 
at least three of six associated symptoms, present 
more days than not for at least six months, and asso-
ciated with significant distress or impairment; an 
additional requirement is that DSM-IV diagnostic 
hierarchy and organic exclusion rules must be met. 
DSM-5 GAD diagnoses generated for this chapter 
were identical to the DSM-IV diagnoses except that 
they allowed GAD to be diagnosed even when the 
symptoms occurred exclusively during episodes of a 
mood disorder.
Results
Prevalence
Prevalence increased substantially from DSM-IV 
to DSM-5 (Table 6.1). DSM-IV GAD has a lifetime 
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Chapter 6: Generalized Anxiety Disorder
Table 6.1 Prevalence of DSM-IV and DSM-5 generalized anxiety disorder in the World Mental Health Surveys
Country Lifetime prevalence 12-month prevalence 30-day prevalence Sample 
size usedDSM-IV DSM-5 % change DSM-IV DSM-5 % change DSM-IV DSM-5 % change
% SE % SE % SE % SE % SE % SE
Low/lower-middle-income 1.1 (0.1) 1.6 (0.1) 45.5 0.6 (0.1) 0.9 (0.1) 50.0 0.3 (0.0) 0.5 (0.1) 66.7 36,498
Colombia 1.3 (0.3) 1.9 (0.3) 46.2 0.6 (0.2) 1.0 (0.2) 66.7 0.3 (0.1) 0.4 (0.1) 33.3 4,426
Iraq 3.7 (0.5) 5.0 (0.6) 35.1 2.3 (0.3) 3.0 (0.4) 30.4 1.4 (0.3) 2.0 (0.3) 42.9 4,332
Nigeria 0.1 (0.0) 0.1 (0.0) 0.0 0.03 (0.0) 0.03 (0.0) 0.0 – – – – 0.0a 6,752
Peru 0.7 (0.1) 1.1 (0.1) 57.1 0.2 (0.1) 0.5 (0.1) 150.0 – – 0.1 (0.0) –b 3,930
PRC (Beijing/Shanghai) 0.8 (0.1) 1.0 (0.1) 25.0 0.5 (0.1) 0.6 (0.1) 20.0 0.3 (0.1) 0.3 (0.1) 0.0 5,201
PRC (Shenzhen) 0.1 (0.0) 0.2 (0.1) 100.0 0.04 (0.0) 0.1 (0.1) 150.0 – – – – 0.0a 7,132
Ukraine 2.0 (0.2) 3.3 (0.3) 65.0 1.0 (0.1) 2.1 (0.2) 110.0 0.6 (0.1) 1.3 (0.1) 116.7 4,725
Upper-middle-income 2.1 (0.1) 2.8 (0.1) 33.3 1.1 (0.1) 1.6 (0.1) 45.5 0.4 (0.0) 0.7 (0.1) 75.0 28,927
Brazil 3.7 (0.3) 5.1 (0.4) 37.8 2.3 (0.2) 3.3 (0.3) 43.5 1.0 (0.1) 1.8 (0.2) 80.0 5,037
Bulgaria 1.7 (0.2) 2.3 (0.2) 35.3 0.9 (0.1) 1.2 (0.1) 33.3 0.3 (0.1) 0.5 (0.1) 66.7 5,318
Colombia (Medellín) 2.6 (0.4) 3.8 (0.5) 46.2 1.2 (0.3) 2.1 (0.3) 75.0 0.4 (0.1) 0.9 (0.2) 125.0 3,261
Lebanon 2.0 (0.3) 2.3 (0.3) 15.0 1.2 (0.3) 1.5 (0.3) 25.0 0.5 (0.2) 0.6 (0.2) 20.0 2,857
Mexico 0.9 (0.1) 1.1 (0.2) 22.2 0.4 (0.1) 0.6 (0.1) 50.0 0.2 (0.1) 0.3 (0.1) 50.0 5,782
Romania 0.8 (0.2) 1.0 (0.3) 25.0 0.2 (0.1) 0.2 (0.1) 0.0 0.1 (0.1) 0.2 (0.1) 100.0 2,357
South Africa 2.5 (0.3) 3.6 (0.4) 44.0 1.4 (0.2) 1.9 (0.3) 35.7 0.4 (0.1) 0.6 (0.1) 50.0 4,315
High-income 3.7 (0.1) 5.0 (0.1) 35.1 1.5 (0.1) 2.3 (0.1) 53.3 0.6 (0.0) 0.9 (0.0) 50.0 81,836
Australia 6.0 (0.4) 8.0 (0.5) 33.3 2.2 (0.3) 3.6 (0.3) 63.6 0.8 (0.2) 1.5 (0.2) 87.5 8,460
Belgium 1.9 (0.4) 2.8 (0.5) 47.4 0.6 (0.2) 0.9 (0.3) 50.0 0.2 (0.1) 0.3 (0.1) 50.0 2,419
France 4.9 (0.5) 6.2 (0.5) 26.5 1.5 (0.3) 2.1 (0.3) 40.0 0.5 (0.2) 0.6 (0.2) 20.0 2,894
Germany 1.1 (0.2) 1.5 (0.2) 36.4 0.3 (0.1) 0.5 (0.1) 66.7 0.2 (0.1) 0.2 (0.1) 0.0 3,555
Israel 3.3 (0.3) 4.4 (0.3) 33.3 2.2 (0.2) 3.1 (0.3) 40.9 0.7 (0.1) 1.1 (0.2) 57.1 4,859
Italy 1.4 (0.2) 2.1 (0.3) 50.0 0.4 (0.1) 0.6 (0.1) 50.0 0.1 (0.0) 0.2 (0.1) 100.0 4,712
Japan 1.9 (0.2) 2.6 (0.3) 36.8 0.9 (0.1) 1.2 (0.2) 33.3 0.1 (0.1) 0.2 (0.1) 100.0 4,129
New Zealand 6.2 (0.3) 7.9 (0.3) 27.4 2.1 (0.2) 3.1 (0.2) 47.6 0.8 (0.1) 1.2 (0.1) 50.0 12,790
Northern Ireland 4.1 (0.4) 6.4 (0.4) 56.1 1.9 (0.3) 2.8 (0.3) 47.4 1.0 (0.2) 1.5 (0.2) 50.0 4,340
Poland 0.7 (0.1) 0.9 (0.1) 28.6 0.5 (0.1) 0.5 (0.1) 0.0 0.2 (0.1) 0.3 (0.1) 50.0 10,081
Portugal 4.3 (0.4) 6.1 (0.5) 41.9 2.1 (0.2) 3.3 (0.3) 57.1 0.7 (0.1) 1.1 (0.2) 57.1 3,849
Spain 1.3 (0.2) 1.9 (0.2) 46.2 0.5 (0.1) 0.8 (0.2) 60.0 0.2 (0.1) 0.4 (0.1) 100.0 5,473
Spain (Murcia) 4.7 (0.8) 7.0 (0.9) 48.9 3.0 (0.7) 4.3 (0.7) 43.3 2.1 (0.5) 3.0 (0.6) 42.9 2,621
Netherlands 2.6 (0.4) 3.6 (0.4) 38.5 0.6 (0.2) 1.0 (0.2) 66.7 0.2 (0.1) 0.4 (0.1) 100.0 2,372
United States 5.7 (0.3) 7.8 (0.3) 36.8 2.7 (0.2) 4.0 (0.2) 48.1 1.0 (0.1) 1.6 (0.2) 60.0 9,282
All countries combined 2.7 (0.1) 3.7 (0.1) 37.0 1.2 (0.0) 1.8 (0.1) 50.0 0.5 (0.0) 0.8 (0.0) 60.0 147,261
Comparison between  
countriesc
F28,ν = 76.8*,  
P < 0.001
F28,ν = 85.8*,  
P < 0.001
F28,ν = 38.8*,  
P < 0.001
F28,ν = 42.7*,  
P < 0.001
F28,ν = 20.5*,  
P < 0.001
F28,ν = 29.0*,  
P < 0.001
Comparison low-, middle-, and 
high-income country groupsc
F2,ν = 253.3*,  
P < 0.001
F2,ν = 311.3*,  
P < 0.001
F2,ν = 85.0*,  
P < 0.001
F2,ν = 106.5*,  
P < 0.001
F2,ν = 16.5*,  
P < 0.001
F2,ν = 21.7*,  
P < 0.001
Values represent % (SE).
Dashed lines indicate empty cells.
aAs the numerator and denominator are both zero, a value of 0.0 is shown for per cent change.
bThe amount of change is greater than zero, but percent change could not be calculated because the denominator is zero.
cWald design-corrected F-tests were used to determine if there is variation in prevalence estimates across countries. The denominator degree of freedom, ν, is 5429.
PRC: People’s Republic of China.
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Section II: The Disorders
prevalence of 2.7%, 12-month prevalence of 1.2%, and 
30-day prevalence of 0.5% in the total sample. By con-
trast, DSM-5 GAD has a lifetime prevalence of 3.7%, 
an increase of 37% over the rate for DSM-IV GAD. The 
increases are even larger for recent cases: 12-month 
prevalence rose to 1.8% (an increase of 50%) and 30-day 
prevalence rose to 0.8% (an increase of 60%) following 
the diagnostic revision. Both GAD diagnoses are most 
prevalent in high-income countries, less prevalent in 
upper-middle-income countries, and least prevalent 
in low/lower-middle-income countries. Nevertheless, 
DSM-5 GAD is more prevalent than DSM-IV GAD in 
all three country income groups. In fact, with the excep-
tion of Nigeria, for which no change was observed, the 
lifetime prevalence of GAD increased from DSM-IV to 
DSM-5 in every country examined here.
Comorbidity
Comorbidity also increased from DSM-IV to DSM-5 
(Table 6.2). In DSM-IV, more than three-quarters 
(75.6%) of respondents with lifetime GAD, and more 
than half (57.1%) of those with 12-month GAD, qualify 
for at least one other mental disorder assessed by the 
CIDI. Comorbidity is equally common with mood and 
anxiety disorders, whether assessed over the respond-
ent’s lifetime (50.4% mood vs. 49.2% anxiety) or in the 
12 months before interview (33.3% mood vs. 34.5% anx-
iety); comorbidity is less common with substance-use 
disorders and least common with disruptive  behaviour/
impulse-control disorders. Even with the DSM-IV hier-
archy rule in effect, MDD is by far the single most com-
mon comorbid condition (reported by 42.2% of lifetime 
DSM-IV GAD cases), followed by social anxiety disor-
der (25.3%) and specific phobia (24.9%). Interestingly, 
DSM-IV GAD typically develops later than comorbid 
disorders: GAD precedes other anxiety disorders in only 
12.7% of cases, disruptive behaviour/impulse-control 
disorders in 33.5% of cases, and mood and substance-
use disorders in about 40% of cases.
In DSM-5, rates of comorbidity rose to 81.9% 
among lifetime cases and to 70.8% among 12-month 
cases of GAD. As expected, the largest change from 
DSM-IV is in comorbidity with mood disorders, which 
are present in the majority of individuals with life-
time (63.0%) and 12-month (51.3%) GAD. Although 
the number of GAD cases with comorbid MDD far 
exceeds the number with bipolar spectrum disorder, 
the percent change in comorbidity is strikingly similar 
for unipolar and bipolar mood disorders: both increase 
by nearly 25% among lifetime GAD cases and by more 
than 50% among 12-month GAD cases when the hier-
archy rule is eliminated. As a result, the proportion of 
GAD cases with comorbid mood disorders outnum-
bers the proportion with comorbid anxiety disorders 
in DSM-5. Nevertheless, rates of comorbid anxiety, 
substance-use, and disruptive behaviour/impulse-
control disorders are all higher for DSM-5 than 
DSM-IV GAD, suggesting that new cases captured by 
the revised diagnostic criteria have higher overall lev-
els of comorbidity than previously identified cases. The 
new cases also disproportionately experience GAD as 
a temporally secondary disorder. For example, under 
DSM-5, 75% of respondents with a lifetime history 
of both GAD and a mood disorder report that GAD 
began after the mood disorder.
Role Impairment
DSM-5 GAD is associated with greater role impair-
ment than DSM-IV GAD. Respondents with DSM-IV 
GAD report a mean of 33.9 days (SE = 2.6) out of role 
due to GAD in the past 12 months, compared to a mean 
of 41.2 days (SE = 2.4) for those with DSM-5 GAD (data 
not shown). On the Sheehan Disability Scales, severe 
functional impairment in one or more life domains is 
reported by 45.7% of those with DSM-IV GAD versus 
50.6% of those with DSM-5 GAD (Table 6.3). Severe 
impairment is most common in the social domain and 
least common in the home domain, regardless of GAD 
definition. In addition, GAD is more disabling in high-
income countries than in the upper-middle- or low/
lower-middle-income countries under both defini-
tions. Interestingly, although the number of GAD cases 
with severe impairment increased in all three country 
income groups in DSM-5, the proportion of severely 
disabled cases increased more in high- and upper-
middle-income countries (11–12% higher than in 
DSM-IV) than in low/lower-middle-income countries 
(4% higher than in DSM-IV).
Treatment
DSM-5 GAD is associated with a small but consist-
ent increase in treatment seeking over DSM-IV GAD 
(Table 6.4). A total of 44.1% of respondents with 
DSM-IV GAD sought treatment for some type of 
mental health or substance-use problem during 
the year before interview, compared to 49.2% of those 
with DSM-5 GAD. Individuals with GAD, regardless 
of diagnostic definition, sought treatment most often 
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DSM-IV disorder DSM-IV DSM-5
Lifetime 
comorbiditya
12-month 
comorbidityb
Temporal priority 
of GADc
Lifetime 
comorbiditya
12-month 
comorbidityb
Temporal priority 
of GADc
I. Mood disorder
Major depressive disorder 42.2 (1.1) 26.8 (1.4) 52.6 (0.9) 40.9 (1.3)
Bipolar spectrum disorderd 9.2 (0.6) 7.0 (0.8) 11.4 (0.6) 10.8 (0.8)
Any mood disordere 50.4 (1.1) 33.3 (1.5) 40.5 (1.6) 63.0 (0.9) 51.3 (1.3) 24.6 (1.1)
II. Anxiety disorder
Panic disorder 11.3 (0.8) 8.3 (0.9) 12.3 (0.7) 11.8 (0.9)
Social anxiety disorder 25.3 (1.0) 18.5 (1.3) 26.1 (0.9) 22.6 (1.2)
Specific phobia 24.9 (1.0) 22.4 (1.4) 25.6 (0.8) 25.2 (1.2)
Agoraphobia 8.2 (0.6) 6.5 (0.8) 9.4 (0.5) 9.0 (0.7)
Posttraumatic stress disorder 18.7 (0.8) 3.7 (0.5) 21.0 (0.7) 14.4 (0.8)
Childhood-onset separation anxiety disorderf 8.9 (0.9) – 8.6 (0.7) –
Adult-onset separation anxiety disorder 13.6 (1.0) 5.7 (0.9) 15.8 (0.8) 6.9 (0.8)
Any anxiety disorder 49.2 (1.1) 34.5 (1.5) 12.7 (1.0) 51.7 (0.9) 44.0 (1.2) 11.6 (0.8)
III. Disruptive behaviour/Impulse-control disorder
Intermittent explosive disorder 14.4 (1.3) 11.0 (1.7) 15.0 (1.1) 12.1 (1.4)
Binge-eating disorder 5.8 (0.7) 3.6 (0.9) 6.1 (0.6) 4.3 (0.8)
Bulimia nervosa 3.8 (0.5) 1.7 (0.5) 3.8 (0.4) 2.4 (0.5)
Conduct disorder 8.4 (1.0) 0.3 (0.2) 7.8 (0.8) 1.0 (0.3)
Attention-deficit/hyperactivity disorder 7.0 (0.8) 4.3 (0.9) 7.5 (0.8) 5.8 (0.9)
Oppositional defiant disorder 10.7 (1.1) 1.8 (0.6) 10.7 (0.9) 3.5 (0.7)
Any disruptive behaviour/impulse-control disorder 9.9 (0.7) 7.5 (0.9) 33.5 (2.9) 10.1 (0.6) 8.1 (0.8) 29.8 (2.4)
IV. Substance-use disorder
Alcohol abuse 19.4 (0.9) 4.6 (0.6) 19.6 (0.8) 5.8 (0.6)
Alcohol dependence 8.2 (0.6) 3.0 (0.5) 8.9 (0.5) 4.4 (0.6)
Drug abuse 9.6 (0.7) 2.8 (0.6) 10.5 (0.6) 3.6 (0.6)
Drug dependence 4.4 (0.4) 1.5 (0.3) 5.3 (0.4) 2.5 (0.5)
Any substance-use disorder 22.6 (1.0) 7.7 (0.9) 40.3 (2.3) 22.5 (0.8) 9.1 (0.8) 37.2 (1.9)
V. Any mental disorder 75.6 (0.9) 57.1 (1.6) 16.0 (1.0) 81.9 (0.7) 70.8 (1.2) 11.0 (0.7)
Values represent % (SE).
aProportion of respondents with lifetime DSM-IV or DSM-5 GAD who also qualified for the lifetime DSM-IV disorder in each row.
bProportion of respondents with 12-month DSM-IV or DSM-5 GAD who also qualified for the 12-month DSM-IV disorder in each row.
cProportion of respondents with lifetime DSM-IV or DSM-5 GAD and at least one disorder in the designated disorder class, whose age-of-onset of GAD is reported to be younger than 
the age-of-onset of all comorbid disorders in that class.
dIncludes bipolar I disorder, bipolar II disorder, or subthreshold bipolar disorder.
eIncludes major depressive episode and bipolar spectrum disorder.
fThe surveys did not include a 12-month assessment of childhood-onset separation anxiety disorder.
Table 6.2 Comorbidity of DSM-IV and DSM-5 generalized anxiety disorder with DSM-IV mental disorders, all countries combined
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Section II: The Disorders
in general medical settings, less often in specialty men-
tal health settings, and very rarely in human services 
or complementary-alternative settings. Help-seeking 
patterns differ greatly by country income, with very 
few GAD cases by either definition receiving specialty 
mental health treatment in low /lower-middle-income 
countries, and with a far higher rate of treatment over-
all in high-income than upper-middle- or low/lower-
middle-income countries. Despite these broader 
patterns, treatment seeking is higher for DSM-5 than 
DSM-IV GAD in all three country income groups.
Course and Correlates
DSM-IV and DSM-5 GAD have a similar course of 
illness. Median age-of-onset (AOO) (ages 38 and 
39 for DSM-IV and DSM-5 GAD, respectively) and 
cumulative AOO distributions are nearly identi-
cal for the two diagnoses (Table 6.5). GAD typi-
cally begins after puberty: only 5% of cases develop 
by age 13. New cases emerge gradually through 
adolescence and adulthood, with one-quar-
ter of GAD cases beginning by ages 24–25, half 
Table 6.3 Severity of role impairment (Sheehan Disability Scale) associated with 
12-month DSM-IV and DSM-5  generalized anxiety disorder, by country income group
Proportion with severe role  
impairment (SDS score: 7-10)
DSM-IV DSM-5
% SE % SE
Home
Low/lower-middle-income countries 18.9 3.0 23.2 2.8
Upper-middle-income countries 22.2 3.1 25.8 2.2
High-income countries 26.1 1.6 29.4 1.3
All countries combined 24.7 1.3 28.0 1.1
Comparison between low-, middle-,   
and high-income countriesa
F2,ν = 2.4,  
P = 0.092
F2,ν = 2.5,  
P = 0.081
Work
Low/lower-middle-income countries 22.0 3.7 23.7 3.3
Upper-middle-income countries 21.2 3.0 28.7 3.0
High-income countries 29.7 1.7 34.4 1.4
All countries combined 27.4 1.4 32.1 1.2
Comparison between low-, middle-,  
and high-income countriesa
F2,ν = 4.0*,  
P = 0.018
F2,ν = 5.4*,  
P = 0.005
Relationship
Low/lower-middle-income countries 24.7 4.5 26.1 3.4
Upper-middle-income countries 23.6 2.8 26.8 2.2
High-income countries 27.6 1.6 33.0 1.3
All countries combined 26.6 1.4 31.1 1.1
Comparison between low-, middle-,   
and high-income countriesa
F2,ν = 0.9,  
P = 0.427
F2,ν = 4.1*,  
P = 0.016
Social
Low/lower-middle-income countries 27.3 4.7 24.6 3.7
Upper-middle-income countries 24.2 2.9 28.4 2.8
High-income countries 32.8 1.8 38.1 1.4
All countries combined 30.7 1.5 34.9 1.2
Comparison between low-, middle-,  
and high-income countriesa
F2,ν = 3.2*,  
P = 0.039
F2,ν = 9.6*,  
P < 0.001
Anyb
Low/lower-middle-income countries 37.5 4.7 39.0 3.6
Upper-middle-income countries 38.1 3.4 42.6 3.0
High-income countries 49.0 1.8 54.5 1.4
All countries combined 45.7 1.5 50.6 1.2
Comparison between low-, middle-,   
and high-income countriesa
F2,ν = 5.8*,  
P = 0.003
F2,ν = 13.0*,  
P < 0.001
*Significant at the 0.05 level, two-sided test.
aWald design-corrected F-tests were used to determine if there is variation in impairment severity 
across country income groups. The denominator degree of freedom, ν, is 5429.
bHighest severity category across the four SDS role domains.
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beginning by ages 38–39, and three-quarters begin-
ning by age 53. Only 10% of first onsets occur in 
adults aged 65 or older. Once GAD begins, it often 
persists: 44.8% of individuals with DSM-IV GAD 
and 48.8% of individuals with DSM-5 GAD in their 
lifetime still had the disorder in the year before inter-
view. Onsets are somewhat earlier and course is less 
persistent in high-income countries than in upper-
middle- or low/lower-middle-income countries for 
both GAD diagnoses (data not shown).
Table 6.4 Among those with 12-month DSM-IV and DSM-5 generalized anxiety disorder, percent 
reporting treatment in the past 12 months
Sector of treatment DSM-IV DSM-5
% SE % SE
Specialty mental healthb
Low/lower-middle-income countries 1.3 0.6 3.7 1.4
Upper-middle-income countries 12.0 2.1 16.5 2.3
High-income countries 27.4 1.7 32.3 1.3
All countries combined 21.6 1.3 26.0 1.1
Comparison between low-, middle-,  
and high-income countriesa
F2,ν = 55.2*,  
P < 0.001
F2,ν = 72.1*,  
P < 0.001
General medicalc
Low/lower-middle-income countries 11.5 2.9 11.4 2.2
Upper-middle-income countries 13.6 2.1 14.7 2.0
High-income countries 37.2 1.7 41.0 1.4
All countries combined 29.9 1.3 32.8 1.1
Comparison between low-, middle-,  
and high-income countriesa
F2,ν = 42.5*,  
P < 0.001
F2,ν = 76.8*,  
P < 0.001
Human servicesd
Low/lower-middle-income countries 5.1 2.8 6.4 2.2
Upper-middle-income countries 3.0 1.1 3.8 1.0
High-income countries 6.4 1.0 7.6 0.8
All countries combined 5.6 0.8 6.8 0.6
Comparison between low-, middle-,  
and high-income countriesa
F2,ν = 2.6,  
P = 0.08
F2,ν = 4.7*,  
P = 0.01
Complementary-alternative medicinee
Low/lower-middle-income countries 3.1 1.4 2.4 0.9
Upper-middle-income countries 2.5 1.0 4.0 1.5
High-income countries 7.2 0.8 8.2 0.8
All countries combined 5.9 0.6 6.8 0.1
Comparison between low-, middle-,  
and high-income countriesa
F2,ν = 7.4*,  
P < 0.001
F2,ν = 12.0*,  
P < 0.001
Any treatmentf
Low/lower-middle-income countries 19.6 4.1 21.7 3.3
Upper-middle-income countries 24.5 2.9 29.1 2.8
High-income countries 53.3 1.6 59.0 1.3
All countries combined 44.1 1.4 49.2 1.2
Comparison between low-, middle-,  
and high-income countriesa
F2,ν = 45.3*,  
P < 0.001
F2,ν = 73.6*,  
P < 0.001
*Significant at the 0.05 level, two-sided test.
aWald design-corrected F-tests were used to determine if there is variation in treatment estimates across 
country income groups. The denominator degree of freedom, ν, is 5429.
bThe mental health specialist sector, which includes psychiatrist and non-psychiatrist mental health specialists 
(psychiatrist, psychologist or other non-psychiatrist mental health professional; social worker or counsellor in a 
mental health specialty setting; use of a mental health helpline; or overnight admissions for a mental health or 
drug or alcohol problems, with a presumption of daily contact with a psychiatrist).
cThe general medical sector (general practitioner, other medical doctor, nurse, occupational therapist or any 
healthcare professional).
dThe human services sector (religious or spiritual advisor or social worker or counsellor in any setting other 
than a specialty mental health setting).
eThe CAM (complementary and alternative medicine) sector (any other type of healer, such as herbalist or 
homeopath, participation in an internet support group, or participation in a self-help group).
fAny treatment listed above.
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Table 6.5 Cumulative age-of-onset distributions for DSM-IV and DSM-5 generalized anxiety disorder (GAD), by country 
income group
DSM edition Ages at selected percentiles Projected  
risk at age 75
5 10 25 50 75 90 95 99 % (SE)
DSM-IV
Low/lower-middle-income countries 14 18 28 44 56 70 70 74 2.6 (0.4)
Upper-middle-income countries 14 18 29 44 64 72 73 73 5.1 (0.6)
High-income countries 12 14 22 35 50 60 67 73 6.0 (0.2)
All countries combined 13 15 24 38 53 65 71 73 5.1 (0.2)
DSM-5
Low/lower-middle-income countries 15 18 28 43 56 66 70 74 3.7 (0.4)
Upper-middle-income countries 14 18 29 43 62 72 72 73 6.7 (0.6)
High-income countries 13 14 23 36 50 61 68 74 8.7 (0.4)
All countries combined 13 16 25 39 53 65 70 74 7.3 (0.3)
Values represent ages at selected percentiles on the standardized age-of-onset (AOO) distributions for DSM-IV and DSM-5 GAD. 
These values, and the projected lifetime risk of GAD at age 75, are based on survival models.
DSM-IV and DSM-5 GAD also have very simi-
lar socio-demographic correlates (Table 6.6). Both 
lifetime diagnoses are more prevalent among young 
(under age 60), female, and previously married indi-
viduals. Both are also more prevalent among individu-
als with less education, a lower household income, and 
‘other’ employment status (mostly unemployed or dis-
abled), although these three variables are consistently 
associated with GAD only in high-income countries. 
Socio-demographic correlates of 30-day GAD are 
also very similar regardless of how the disorder was 
defined. Where correlates for 30-day GAD deviate 
from the profile for lifetime cases (e.g., weaker asso-
ciations with age; elevated odds among homemak-
ers as well as those of ‘other’ employment status), the 
deviations are evident for both DSM-IV and DSM-5 
GAD. In spite of these similarities, the associations 
with socio-demographic variables generally are a 
bit larger, show a clearer dose-response gradient, 
and are more consistent across lifetime and 30-day 
analyses for DSM-5 than DSM-IV GAD. Likewise, 
socio- demographic predictors of course (disorder 
persistence) are similar for the two diagnoses, but 
slightly more robust for DSM-5 GAD. Neither female 
gender nor previously married status is associated 
with a more persistent course of illness. Instead, GAD 
is more persistent among individuals with an earlier 
onset of GAD, lower education and family income, 
and – for DSM-5 GAD – lack of employment outside 
the home (‘other’ status or homemaker).
Discussion
The challenge of separating clinically significant anxi-
ety from normal anxiety and from other forms of emo-
tional disturbance has spurred repeated revisions of the 
definition of GAD. The decision in DSM-5 to remove 
GAD’s hierarchical relationship with the mood disor-
ders raises new opportunities for understanding GAD 
and describing its connections to other disorders. In this 
chapter we examined the implications of this decision 
for the epidemiology of GAD in a large, multinational 
sample. Eliminating the hierarchy rule led to an influx of 
new GAD cases: prevalence estimates increased by 37% 
for lifetime GAD, by 50% for 12-month GAD, and by 
60% for 30-day GAD compared to DSM-IV estimates 
in the same surveys. Notably, the prevalence estimates 
reported here for the broadened DSM-5 diagnosis are 
still lower than those published for DSM-IV GAD in 
reviews of previous epidemiological surveys (Somers 
et al. 2006). This appears to be due mainly to the lower 
prevalence of GAD in low/lower-middle-income coun-
tries, which were excluded from earlier reviews. Our 
results highlight the importance of studying GAD in 
developing as well as developed countries, given reli-
able differences not only in prevalence but also in degree 
of role impairment, patterns of treatment seeking, and 
course of illness across country groups (see also Ruscio 
et al. 2017). At the same time, the results show consist-
ently that DSM-5 GAD is more prevalent and severe 
than DSM-IV GAD across countries, irrespective of 
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(cont.)
Variable DSM-IV DSM-5
Lifetime GADa 30-day GADb 12-month GAD/
lifetime casesc
Lifetime GADa 30-day GADb 12-month GAD/
lifetime casesc
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age-cohort –
18–29 4.8*           (4.0–5.7) 0.9             (0.7–1.2) – 6.0*           (5.1–7.0) 0.9        (0.7–1.2) –
30–44 4.0*           (3.5–4.5) 1.2             (1.0–1.6) – 4.8*           (4.3–5.4) 1.4*        (1.1–1.6) –
45–59 2.6*           (2.3–2.9) 1.3             (1.0–1.6) – 3.0*           (2.7–3.3) 1.4*         (1.2–1.8) –
60+ 1.0 1.0 – 1.0 1.0 –
χ2 (P Value)d 445.2         (<0.001) 10.9              (0.012) – 743.8          (<0.001) 32.1         (<0.001) –
Age-of-onset
Early – – 1.7*             (1.3–2.3) – – 1.8*         (1.5–2.3)
Early-average – – 1.4*             (1.1–1.7) – – 1.2*         (1.0–1.5)
Late-average – – 1.1               (0.8–1.3) – – 1.0         (0.8–1.2)
Late – – 1.0 – – 1.0
χ2 (P Value)d – – 20.8             (<0.001) – – 45.9         (<0.001)
Gender
Female 1.7*           (1.6–1.9) 1.8*             (1.5–2.2) 1.1              (0.9–1.3) 1.8*        (1.7–2.0) 1.9*         (1.6–2.3) 1.1        (0.9–1.3)
Male 1.0 1.0 1.0 1.0 1.0 1.0
χ2 (P Value)d 196.9         (<0.001) 32.8           (<0.001) 1.1               (0.306) 313.2         (<0.001) 53.5         (<0.001) 1.3         (0.249)
Marital status
Never married 1.1           (1.0–1.2) 0.8              (0.6–1.0) 0.9              (0.8–1.2) 1.2*         (1.1–1.3) 0.9        (0.7–1.0) 1.1         (0.9–1.3)
Divorced/separated/widowed 1.5*           (1.3–1.6) 1.5*              (1.2–1.8) 1.0              (0.8–1.2) 1.6*            (1.5–1.8) 1.7*         (1.4–2.0) 1.1         (0.9–1.3)
Currently married 1.0 1.0 1.0 1.0 1.0 1.0
χ2 (P Value)d 59.4            (<0.001) 12.3              (0.002) 0.3               (0.871) 131.4         (<0.001) 33.4         (<0.001) 1.0          (0.604)
Education level
No education 1.7*        (1.3–2.3) 3.0*              (1.8–5.2) 1.5              (0.8–2.7) 1.8*           (1.4–2.3) 3.1*        (2.0–4.8) 1.4        (0.8–2.3)
Some primary 1.4*        (1.2–1.7) 2.1*              (1.4–3.0) 1.7*            (1.2–2.4) 1.4*           (1.2–1.6) 2.1*        (1.6–2.9) 1.9*         (1.4–2.5)
Finished primary 1.5*        (1.3–1.8) 2.2*             (1.5–3.3) 1.8*            (1.2–2.7) 1.6*           (1.3–1.8) 2.4*        (1.7–3.3) 1.7*        (1.2–2.3)
Some secondary 1.3*        (1.2–1.5) 1.8*             (1.3–2.4) 1.4*             (1.1–1.8) 1.4*           (1.3–1.6) 2.1*        (1.6–2.6) 1.5*         (1.2–1.8)
Finished secondary 1.2*         (1.1–1.4) 1.3              (0.9–1.8) 1.4*            (1.1–1.8) 1.2*           (1.1–1.4) 1.5*        (1.1–1.9) 1.3*         (1.0–1.6)
Some college 1.2*           (1.0–1.3) 1.2             (0.9–1.6) 1.1              (0.9–1.4) 1.3*           (1.1–1.4) 1.4*        (1.1–1.8) 1.1         (0.9–1.4)
Finished college 1.0 1.0 1.0 1.0 1.0 1.0
χ2 (P Value)d 35.6            (<0.001) 36.4              (<0.001) 16.5             (0.011) 54.1          (<0.001) 58.6         (<0.001) 24.2         (0.001)
Table 6.6 Bivariate associations of socio-demographic correlates with DSM-IV and DSM-5 generalized anxiety disorder (GAD), all countries combined
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Variable DSM-IV DSM-5
Lifetime GADa 30-day GADb 12-month GAD/
lifetime casesc
Lifetime GADa 30-day GADb 12-month GAD/
lifetime casesc
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Household income
Low 1.2*         (1.1–1.3) 1.4*             (1.1–1.8) 1.4*             (1.1–1.8) 1.3*         (1.1–1.4) 1.7*        (1.4–2.1) 1.6*        (1.3–2.0)
Low-average 1.1        (1.0–1.3) 1.2             (1.0–1.6) 1.3*             (1.0–1.6) 1.2*        (1.0–1.3) 1.3*         (1.0–1.6) 1.4*         (1.1–1.7)
High-average 1.1*        (1.0–1.3) 1.2              (0.9–1.6) 1.4*             (1.1–1.7) 1.1*        (1.0–1.3) 1.2        (1.0–1.5) 1.3*        (1.1–1.6)
High 1.0 1.0 1.0 1.0 1.0 1.0
χ2 (P Value)d 8.1          (0.045) 6.5               (0.089) 9.0               (0.029) 20.8          (<0.001) 24.8         (<0.001) 22.1          (<0.001)
Employment status
Student 1.0         (0.8–1.3) 0.9              (0.6–1.5) 1.3              (0.8–2.1) 1.2         (0.9–1.5) 1.1         (0.7–1.7) 1.5        (1.0–2.4)
Homemaker 1.1         (0.9–1.2) 1.5*             (1.1–2.0) 1.1              (0.9–1.4) 1.1         (1.0–1.2) 1.5*         (1.2–1.9) 1.2*        (1.0–1.5)
Retired 0.9*         (0.7–1.0) 0.9             (0.6–1.2) 1.2               (0.9–1.6) 0.9              (0.8–1.0) 0.8        (0.7–1.1) 1.2        (1.0–1.5)
Other 1.6*         (1.4–1.8) 2.2*              (1.8–2.8) 1.3              (1.0–1.6) 1.7*        (1.5–1.9) 2.4*         (2.0–2.9) 1.6*         (1.3–2.0)
Employed 1.0 1.0 1.0 1.0 1.0 1.0
χ2 (P Value)d 64.6          (<0.001) 51.3              (<0.001) 5.2               (0.272) 113.3         (<0.001) 81.1         (<0.001) 22.7         (<0.001)
*Significant at the 0.05 level, two-sided test.
Dashed lines indicate empty cells.
aBased on survival models adjusted for age-cohorts, gender, person-years, and country. The denominator used for these estimates is the number of person-years in the survival models  
(N = 6,383,860 for DSM-IV models; N = 6,360,664 for DSM-5 models).
bBased on logistic regression models adjusted for age, gender, and country. The denominator used for these estimates is the number of respondents in the total sample (N = 147,261).
cBased on logistic regression models predicting 12-month GAD among lifetime cases, adjusted for time since GAD onset, age of GAD onset, sex, and country. The denominator used for 
these estimates is the number of lifetime GAD cases (N = 4,262 for DSM-IV models; N = 5,888 for DSM-5 models).
dChi-square test of significant differences between blocks of socio-demographic variables.
Table 6.6 (cont.)
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economic development. This provides some assurance 
that the consequences of the latest GAD revision gen-
eralize to many parts of the world in which the DSM is 
used to inform research, policy, and clinical care.
The diagnostic revision led to several alterations in 
the epidemiology of GAD, suggesting that new cases 
captured by the revised criteria differ in meaningful 
ways from cases identified using DSM-IV criteria. Not 
surprisingly, some of the most notable differences con-
cerned rates and patterns of comorbidity with other dis-
orders. Approximately 82% of individuals with lifetime 
DSM-5 GAD qualified for another lifetime disorder, a 
small increase from the 76% comorbidity estimate for 
DSM-IV GAD. The increase in comorbidity was more 
striking among 12-month GAD cases, with more than 
70% qualifying for another 12-month disorder under 
DSM-5 compared to 57% under DSM-IV. Although 
an increase in comorbidity was expected, the relatively 
larger increase in comorbidity among 12-month cases 
than lifetime cases warrants some consideration. A 
possible methodological explanation is that better 
memory for recent than distant disorders contributed 
to increased reporting of comorbid disorders, includ-
ing hierarchy-triggering mood disorders, in the past 
year (i.e., a recall effect); another possibility is that 
lifetime comorbidity rates were already so high for 
DSM-IV GAD that there was relatively little room for 
comorbidity to increase under DSM-5 (i.e., a ceiling 
effect). An alternative, more substantive explanation is 
that individuals with chronic GAD may be more highly 
concentrated among 12-month cases than among life-
time cases, who include previously remitted cases as 
well as those whose GAD persisted without remission. 
There is some evidence that having a comorbid dis-
order predicts an unremitting course of GAD (Bruce 
et al. 2001). Additionally, unremitting GAD may be a 
marker of greater clinical severity or of exposure to risk 
factors that are particularly severe (e.g., strong genetic 
diathesis) or enduring (e.g., chronic stress), which may 
themselves increase the likelihood of comorbidity.
Predictably, the most significant change in comor-
bidity occurred with mood disorders. Even with the 
DSM-IV hierarchy rule in effect, comorbid MDD was 
present in more than 40% of lifetime GAD cases. When 
the hierarchy rule was lifted, comorbidity increased to 
more than 50%. The increase was even more dramatic 
among respondents who experienced GAD in the past 
year, of whom just over one-quarter were in a major 
depressive episode in the past year under DSM-IV com-
pared to more than 40% under DSM-5. Based on trends 
observed in previous research (Ruscio & Khazanov 
2017), comorbidity rates are likely to be even higher in 
clinical samples. Nevertheless, the finding that about 
half of people with lifetime DSM-5 GAD have never 
had MDD appears to support the continued separation 
of these disorders (Goldberg et al. 2010).
Although our analyses did not directly address 
the question of whether GAD should be considered 
an anxiety disorder or depressive disorder, the results 
do offer some relevant insights. Whereas DSM-IV 
GAD had roughly equal rates of lifetime comorbid-
ity with mood disorders and other anxiety disorders 
(50% versus 49%), DSM-5 GAD had higher comor-
bidity with mood than anxiety disorders (63% versus 
52%). Notably, this deviates from the pattern of sub-
stantially higher comorbidity with anxiety than mood 
 disorders that was observed for every other anxiety 
disorder in the WMH surveys except posttraumatic 
stress disorder, which in DSM-5 is no longer classified 
as an anxiety disorder (see Chapters 7–12 in this vol-
ume). DSM-5 GAD also resembles MDD more closely 
than other anxiety disorders in these surveys in hav-
ing a fairly late AOO, slow accumulation of new cases 
across the lifespan, and relatively less persistent course 
of illness. These epidemiological results are consistent 
with results from large factor analytic studies (Krueger 
1999; Watson 2005) suggesting a closer relationship of 
GAD with depressive disorders than with other anxiety 
disorders. Although the collective findings appear to 
support a departure of GAD from the family of anxiety 
disorders, other considerations may support its con-
tinued classification with these disorders. For example, 
in prospective research, psychosocial risk factors for 
GAD have been shown to align more closely with those 
for anxiety disorders than depressive disorders (Beesdo 
et al. 2010). From a more pragmatic standpoint, focus-
ing on GAD’s prominent anxiety symptoms may help 
promote clinical detection and accurate diagnosis of 
the disorder – an important consideration given that 
GAD remains poorly recognized, especially in general 
medical settings (Wittchen et al. 2002).
Of note, the new cases identified by DSM-5 dispro-
portionately reported that their GAD began after the 
onset of another mental disorder. This diverges from 
conventional clinical wisdom which dictates that anxi-
ety typically precedes depression, as well as from prior 
research which documented a nearly equal number 
of comorbid cases beginning with GAD versus MDD 
(Moffitt et al. 2007). Our research suggests that once 
the hierarchy rule is lifted, an imbalance emerges, with 
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mood disorders (typically MDD) tending to onset 
before GAD. One explanation for this may be meth-
odological; by definition, GAD cases that emerged 
first would not meet the hierarchy rule and would be 
diagnosed by the DSM-IV criteria. Nevertheless, sub-
stantive interpretations are also possible. For example, 
GAD may be a complication of, or a reaction to, a major 
depressive episode, such as when role impairments 
associated with depression create secondary problems 
(e.g., job loss, poor grades, relationship strain) that 
elicit anxiety. A different possibility, consistent with 
the idea that anxiety precedes depression, is that the 
propensity to worry emerges early in life but may not 
be recognized as a problem until a major stressor – or 
perhaps another disorder – undermines the ability to 
manage worry successfully. Research collecting more 
detailed information about the onset of worry as well as 
GAD, and about the environmental contexts in which 
GAD and other disorders first emerge, would aid in 
understanding the causes of GAD and the functional 
relationships between disorders that could be targeted 
in treatment.
Several aspects of the GAD diagnosis, including 
socio-demographic correlates and AOO, remained sta-
ble irrespective of the criterion set applied. Consistent 
with previous epidemiological research (Grant et al. 
2005; Lieb et al. 2005), individuals with GAD were 
more likely to be young (below age 60), female, and 
previously married (divorced, separated, or widowed). 
In high-income countries, GAD was also associated 
with lower education, lower income, and a lack of full-
time employment. These similarities suggest that GAD 
is fundamentally the same disorder, concentrated in 
the same segments of the population, under the two 
diagnostic definitions. At the same time, DSM-5 cases 
tended to report more significant role impairment due 
to GAD, especially in upper-middle- and high-income 
countries, and were correspondingly more likely to seek 
treatment. Taken together, these results suggest that 
the revised criteria were successful in capturing clini-
cally significant cases of GAD that were missed by the 
DSM-IV diagnosis. The greater severity of these cases 
is consistent with prior studies, which found greater 
psychopathology (Zimmerman & Chelminski 2003; 
Lawrence et al. 2009) and a more adverse risk profile 
(Moffitt et al. 2007) among comorbid relative to ‘pure’ 
GAD and MDD. Importantly, the available findings 
do not resolve whether the new cases actually involve 
multiple, distinct disorders (e.g., comorbid GAD and 
MDD) or a severe form of mood disorder (e.g., an 
anxious subtype of MDD); these and another possi-
bilities await evaluation using methods appropriate for 
explicating comorbidity (Klein & Riso 1993; Neale & 
Kendler 1995; J. Ruscio & Ruscio 2004). Nevertheless, 
the observed severity underscores the importance of 
recognizing the significant consequences of co-occur-
ring anxiety in these former hierarchy cases, especially 
as the presence of comorbid GAD may have implica-
tions for treatment (Zimmerman & Chelminski 2003; 
Coplan et al. 2015).
A notable strength of the current study is the 
large, multinational sample that was representative 
of the household populations in the countries and 
regions included here. The large sample size allowed 
for the detection of subtle changes from DSM-IV to 
DSM-5 GAD and increased confidence in the reli-
ability of the findings. The use of representative com-
munity samples ensured that results were not biased 
by self-selection into treatment or by features of spe-
cific clinical sites. The inclusion of 29 surveys from 26 
diverse countries ensured that results were not limited 
to particular regions, cultures, or strata of economic 
development. Nevertheless, the study also had several 
limitations. Perhaps most important, GAD diagnoses 
were assigned based on fully structured interviews 
administered by lay interviewers. Although the CIDI 
shows good concordance with the SCID, it is possible 
that results would have differed if diagnoses had been 
assigned by expert clinicians. This is a particular con-
cern given the challenges of differentiating GAD from 
MDD symptoms and establishing the dates of episode 
onset and remission, even for experienced clinicians. 
Another limitation is that symptom onset was assessed 
retrospectively; consequently, some caution is war-
ranted when interpreting the AOO and temporal pri-
ority data. The timing of GAD and mood disorders was 
determined from these AOO reports along with reports 
of symptom offset and episode duration, which were 
rounded to the nearest year and dated separately for 
each disorder. Consequently, in the common situation 
of two disorders beginning in the same year (Kessler 
et al. 2008), we were unable to distinguish simultane-
ous onsets from onsets that were separated within the 
year. Finally, although considerable effort was made 
to standardize data collection across surveys, cultural 
variation in the interpretation of concepts such as 
‘excessive worry’ and ‘feeling sad, empty, or depressed’ 
may have contributed to cross-national differences.
This chapter presents the first comparison of 
DSM-IV and DSM-5 GAD in the general population. In 
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a large, multinational sample, lifting the DSM-IV hier-
archy with mood disorders increased the prevalence 
of GAD substantially. The newly identified GAD cases 
appeared to be more severe than previously identified 
cases on several dimensions. DSM-5 GAD was associ-
ated with somewhat higher rates of role impairment 
and treatment seeking than DSM-IV GAD. In addition, 
DSM-5 GAD was associated more strongly with 
psychiatric comorbidity in general and MDD comor-
bidity in particular, with most GAD onsets occurring 
after the onset of another mental disorder. These pat-
terns of comorbidity are consistent with findings from 
empirically derived taxonomies, which tend to group 
GAD with depressive disorders rather than anxiety 
disorders. Other important correlates of GAD such as 
female gender, previously married status, lower educa-
tion and income, and a lack of full-time employment 
remained unchanged. Whether DSM-IV or DSM-5 
criteria are applied, these findings converge on a con-
ceptualization of GAD as a common disorder that is 
associated with considerable morbidity and disability.
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